Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 12/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005007 | 0.89 | HTR2C (0.55) | HTR2CDRD2DRD1DRD5DRD3 | |
| SCHEMBL3413391 | 0.77 | HTR2C (0.62) | HTR2CDRD2DRD4HTR2AKMT2A | |
| Prococene I SCHEMBL118080 | 0.73 | HTR2C (0.58) | HTR2CCA2CA5AKMT2A | |
| Prococene I SCHEMBL29794343 | 0.73 | HTR2C (0.58) | HTR2CCA2CA5AKMT2A | |
| SCHEMBL521129 | 0.72 | HTR2C (0.48) | HTR2CCA2DRD2HTR2AKMT2A | |
| SCHEMBL7092152 | 0.71 | HTR2C (0.80) | HTR2CDRD2HTR2AKMT2AHTR2B | |
| SCHEMBL13005016 | 0.70 | DRD2 (0.51) | HTR2CCA2CA5ADRD2DRD1 | |
| SCHEMBL10428639 | 0.70 | HTR2C (0.56) | HTR2CCA2CA5ADRD2DRD3 | |
| SCHEMBL4273935 | 0.70 | OPRD1 (0.54) | HTR2CDRD2DRD1DRD5DRD3 | |
| SCHEMBL8680421 | 0.69 | HTR2C (0.48) | HTR2CCA2CA5AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | HTR2C 154/4885CA2 2200/4885CA5A 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.